Understanding the responsibilities involved in Drug Substance and Drug Product manufacturing is essential for making the right strategic decisions. Many biotech companies approaching clinical phases discover that the distinction between these two stages affects regulatory compliance, timelines, and manufacturing partnerships.

Working with an experienced CDMO is often the most efficient way to manage these responsibilities while maintaining compliance with international regulatory standards.

Drug Substance Manufacturing

Drug Substance refers to the active biological ingredient produced during the upstream and downstream manufacturing process. In biologics production, this often includes recombinant proteins, antibodies, enzymes, or plasmid DNA generated through microbial or mammalian expression systems.

Drug Substance manufacturing typically involves several critical steps:

• Cell line development or strain optimization

• Upstream production (fermentation or cell culture)

• Downstream purification (chromatography, filtration, concentration)

• Analytical characterization

• Bulk storage of the purified active ingredient

These activities must be performed under GMP manufacturing conditions when the material is intended for clinical or commercial use.

A CDMO specializing in biologics manufacturing plays a key role in this stage by ensuring process robustness, scalability, and regulatory compliance. At 53Biologics, for example, our Process Development Services are designed to align development work with future GMP manufacturing requirements, reducing the risk of costly process redesigns later.

Drug Substance production is often the most technically complex stage of biologics manufacturing, requiring deep expertise in both upstream and downstream operations.

Drug Product Manufacturing: From Bulk to Final Formulation

While Drug Substance manufacturing focuses on producing the active ingredient, Drug Product manufacturing involves converting that ingredient into the final medicinal form that will be administered to patients.

This stage typically includes:

• Formulation development

• Sterile filtration

• Fill and finish operations

• Packaging and labeling

• Stability testing

Drug Product manufacturing must also comply with GMP manufacturing regulations, particularly when sterile processes are involved. Any contamination risk or formulation instability at this stage can compromise the entire production batch.

Because Drug Product manufacturing often requires specialized equipment and facilities, many biotech companies rely on a CDMO network where one partner focuses on Drug Substance production and another handles fill-finish operations.

Understanding this division of responsibilities early in development helps ensure proper planning for clinical manufacturing campaigns.

GMP Manufacturing Responsibilities Between Client and CDMO

A common misconception among biotech companies is that outsourcing manufacturing to a CDMO transfers all regulatory responsibilities. In reality, regulatory authorities consider the sponsor company ultimately responsible for product quality.

This means that while the CDMO performs manufacturing activities, the sponsor must still ensure:

• Oversight of the quality system

• Approval of manufacturing changes

• Review of batch documentation

• Compliance with regulatory submissions

At the same time, a reliable CDMO should provide a robust quality framework that supports the sponsor’s regulatory obligations.

Organizations such as the World Health Organization GMP guidelines emphasize the importance of clearly defined roles between manufacturing partners to ensure product safety and traceability.

At 53Biologics, our GMP Manufacturing Services are structured around transparent collaboration with sponsors, ensuring that responsibilities for Drug Substance manufacturing are clearly documented and aligned with regulatory expectations.

When to Engage a CDMO for Drug Substance Manufacturing

For many biotech companies, the decision to engage a CDMO occurs when a lead candidate shows strong preclinical promise and clinical manufacturing becomes imminent.

However, engaging a CDMO earlier can provide several advantages:

• Early identification of scalability challenges

• Alignment between development and GMP manufacturing

• Reduced risk during technology transfer

• Faster readiness for clinical production

At 53Biologics, we support biologics production from early development stages through GMP manufacturing of Drug Substance, enabling companies to build a scalable and compliant manufacturing strategy.

More information about our capabilities can be found on our Biologics Production page.

Why Understanding Drug Substance and Drug Product Responsibilities Matters

For decision-stage biotech companies, understanding the differences between Drug Substance and Drug Product manufacturing is more than a technical detail. It influences:

• Manufacturing timelines

• Regulatory submissions

• Technology transfer strategy

• Selection of CDMO partners

Companies that plan these responsibilities early can significantly reduce development risk and accelerate the path toward clinical manufacturing.

Final Thoughts

Successfully navigating biologics manufacturing requires a clear understanding of the responsibilities involved in Drug Substance, Drug Product, and GMP manufacturing operations. By partnering with an experienced CDMO, biotech companies can focus on advancing their therapeutic candidates while ensuring that manufacturing processes meet the highest regulatory standards.

At 53Biologics, we specialize in Drug Substance manufacturing for biologics, supporting biotech innovators from process development through GMP manufacturing. If your program is approaching clinical manufacturing, engaging the right CDMO partner early can make the difference between delays and a smooth path to the clinic.

About 53Biologics:

53Biologics is a Spanish CDMO specialized in decoding biologics production, from DNA to proteins. The company provide services from preclinical development to GMP manufacturing, supporting their clients in getting their biological products to market as quickly as possible.

For more information or to speak with one of our experts email us at [email protected]